🎯 HCC treatment is evolving…
TACE + immunotherapy + targeted therapy shows stronger outcomes—but are we ready to change practice?
⚠️ Promising data, but guidelines still need phase III confirmation
#GastroAGI #HCC #LiverCancer #TACE #Immunotherapy #TargetedTherapy #Hepatology #Oncology #MedEd
Nutrition is central in cirrhosis care. Malnutrition, sarcopenia, and frailty worsen transplant outcomes.
Early assessment, adequate calories, and high-quality protein prehabilitation preserve muscle and resilience. The waitlist is a window to intervene.
#Cirrhosis #Hepatology #TransplantMedicine #NutritionInCirrhosis #Sarcopenia #MedicalEducation #EvidenceBasedMedicine #GastroAGI
GastroAGI is an AI-powered knowledge platform for gastroenterology & hepatology—built for clinicians, trainees, and researchers.
Evidence-first answers from journals, guidelines, and conferences. No noise. No hallucinations. Just clarity.
#GastroAGI #Gastroenterology #Hepatology #MedicalAI #EvidenceBasedMedicine #MedEd #ClinicalPractice #GIResearch
COBALT Trial (PBC): Despite early termination, adjusted analyses + real-world external controls showed obeticholic acid (OCA) reduces major liver events.
EC (External Control) analysis: 60% risk reduction in the risk of adverse clinical outcomes like death, liver transplantation, or hepatic decompensation.(HR 0.39).
Well-tolerated; pruritus most common.
Highlights power of hybrid RCT + real-world evidence.
🔬 GastroAGI — February 2026 Updates
February updates are live on GastroAGI, covering key areas in gastroenterology and hepatology, including Liver Transplantation, Endoscopy, IBD, GI Oncology, Upper GI disorders, Cirrhosis, and Fatty Liver Disease (MASLD).
Explore more: https://gastroagi.com
Your liver doesn’t complain—it adapts.
That’s why liver disease often goes unnoticed until it’s severe.
Early testing + expert care = better outcomes.
https://drharikumar.com/hepatology/
GastroAGI
All Scientifical
unitedvrg.com
Dr Harikumar